Barriers to antiviral treatment in hepatitis C infected intravenous drug users

G. Gazdag, Gergely Horváth, Olga Szabó, Gabor S. Ungvari

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Nowadays intravenous drug use is the main source of hepatitis C transmission, but only a small proportion of those who acquired infection via intravenous drug use receive antiviral treatment. Aim: to assess the barriers of access to antiviral treatment of infected intravenous drug users. Methods: A retrospective chart review was carried out in a hepatology outpatient clinic including all hepatitis C infected intravenous drug users in a 3-year period. Results: Only one-third of the infected former intravenous drug users received antiviral treatment. The main barrier to antiviral treatment was the lack of abstinence. Former intravenous drug users in prison or in long-term drug rehabilitation institutes were more likely to enter antiviral treatment. Conclusions: The low proportion of patients entering antiviral treatment calls the attention to further improving the pre-treatment management of this patient population. Special attention should be paid to the maintenance of abstinence.

Original languageEnglish
Pages (from-to)459-462
Number of pages4
JournalNeuropsychopharmacologia Hungarica
Volume12
Issue number4
Publication statusPublished - Dec 2010

Fingerprint

Hepatitis C
Drug Users
Antiviral Agents
Therapeutics
Pharmaceutical Preparations
Prisons
Gastroenterology
Ambulatory Care Facilities
Rehabilitation
Maintenance
Infection
Population

Keywords

  • Antiviral treatment
  • Barriers
  • Drug addiction
  • Hepatitis C infection

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Neuropsychology and Physiological Psychology
  • Clinical Neurology

Cite this

Barriers to antiviral treatment in hepatitis C infected intravenous drug users. / Gazdag, G.; Horváth, Gergely; Szabó, Olga; Ungvari, Gabor S.

In: Neuropsychopharmacologia Hungarica, Vol. 12, No. 4, 12.2010, p. 459-462.

Research output: Contribution to journalArticle

Gazdag, G. ; Horváth, Gergely ; Szabó, Olga ; Ungvari, Gabor S. / Barriers to antiviral treatment in hepatitis C infected intravenous drug users. In: Neuropsychopharmacologia Hungarica. 2010 ; Vol. 12, No. 4. pp. 459-462.
@article{5337dc4c07014bfa96eb08206d00021d,
title = "Barriers to antiviral treatment in hepatitis C infected intravenous drug users",
abstract = "Background: Nowadays intravenous drug use is the main source of hepatitis C transmission, but only a small proportion of those who acquired infection via intravenous drug use receive antiviral treatment. Aim: to assess the barriers of access to antiviral treatment of infected intravenous drug users. Methods: A retrospective chart review was carried out in a hepatology outpatient clinic including all hepatitis C infected intravenous drug users in a 3-year period. Results: Only one-third of the infected former intravenous drug users received antiviral treatment. The main barrier to antiviral treatment was the lack of abstinence. Former intravenous drug users in prison or in long-term drug rehabilitation institutes were more likely to enter antiviral treatment. Conclusions: The low proportion of patients entering antiviral treatment calls the attention to further improving the pre-treatment management of this patient population. Special attention should be paid to the maintenance of abstinence.",
keywords = "Antiviral treatment, Barriers, Drug addiction, Hepatitis C infection",
author = "G. Gazdag and Gergely Horv{\'a}th and Olga Szab{\'o} and Ungvari, {Gabor S.}",
year = "2010",
month = "12",
language = "English",
volume = "12",
pages = "459--462",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "4",

}

TY - JOUR

T1 - Barriers to antiviral treatment in hepatitis C infected intravenous drug users

AU - Gazdag, G.

AU - Horváth, Gergely

AU - Szabó, Olga

AU - Ungvari, Gabor S.

PY - 2010/12

Y1 - 2010/12

N2 - Background: Nowadays intravenous drug use is the main source of hepatitis C transmission, but only a small proportion of those who acquired infection via intravenous drug use receive antiviral treatment. Aim: to assess the barriers of access to antiviral treatment of infected intravenous drug users. Methods: A retrospective chart review was carried out in a hepatology outpatient clinic including all hepatitis C infected intravenous drug users in a 3-year period. Results: Only one-third of the infected former intravenous drug users received antiviral treatment. The main barrier to antiviral treatment was the lack of abstinence. Former intravenous drug users in prison or in long-term drug rehabilitation institutes were more likely to enter antiviral treatment. Conclusions: The low proportion of patients entering antiviral treatment calls the attention to further improving the pre-treatment management of this patient population. Special attention should be paid to the maintenance of abstinence.

AB - Background: Nowadays intravenous drug use is the main source of hepatitis C transmission, but only a small proportion of those who acquired infection via intravenous drug use receive antiviral treatment. Aim: to assess the barriers of access to antiviral treatment of infected intravenous drug users. Methods: A retrospective chart review was carried out in a hepatology outpatient clinic including all hepatitis C infected intravenous drug users in a 3-year period. Results: Only one-third of the infected former intravenous drug users received antiviral treatment. The main barrier to antiviral treatment was the lack of abstinence. Former intravenous drug users in prison or in long-term drug rehabilitation institutes were more likely to enter antiviral treatment. Conclusions: The low proportion of patients entering antiviral treatment calls the attention to further improving the pre-treatment management of this patient population. Special attention should be paid to the maintenance of abstinence.

KW - Antiviral treatment

KW - Barriers

KW - Drug addiction

KW - Hepatitis C infection

UR - http://www.scopus.com/inward/record.url?scp=78651358351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651358351&partnerID=8YFLogxK

M3 - Article

C2 - 21220790

AN - SCOPUS:78651358351

VL - 12

SP - 459

EP - 462

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 4

ER -